Spots Global Cancer Trial Database for Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
Official Title: Multicenter Phase 1b/2 Trial Testing Neoadjuvant Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma - MARIANE
Study ID: NCT06240143
Conditions
Study Description
Brief Summary: This open label, single country trial will test if local injection of low-dose ipilimumab and nivolumab, is safe and reduces the sentinel node positivity in high-risk stage II melanoma patients.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Amsterdam University Medical Center, Amsterdam, , Netherlands
Antoni van Leeuwenhoek Hospital, Amsterdam, , Netherlands
University Medical Center Groningen, Groningen, , Netherlands
Leiden University Medical Center, Leiden, , Netherlands
Erasmus University Medical Center, Rotterdam, , Netherlands
University Medical Center Utrecht, Utrecht, , Netherlands
Contact Details
Name: Christian Blank, Prof
Affiliation: Medical oncologist/researcher
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
